Skip to content

EPS (Basic) at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
-$0.67+69.7%
Royalty Pharma logo
Royalty PharmaRPRX
$0.67+21.8%
Theravance Biopharma logo
Theravance BiopharmaTBPH
-$0.10+63.0%
Innoviva, Inc. logo
Innoviva, Inc.INVA
$2.52+441%
Zymeworks logo
ZymeworksZYME
-$0.59-96.7%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$1.84-17.2%

Other financials

Income statement

See full
Revenue$12.3M-22.6%
Operating income-$480.0K-108%
Net income$4.5M+88.6%
EPS (diluted)$0.17+183%

Balance sheet

See full
Cash & equivalents$85.6M-5.2%
Total debt$124.7M+9.0%
Total equity$92.9M+9.7%
Total assets$271.9M+27.8%

Cash flow

See full
Operating cash flow$6.1M+178%
CapEx$3.0K-29.4%
Free cash flow-$2.9M+36.0%

Valuation

See full
Market cap$746.04M+159%
Enterprise value$785.17M+152%
P/E22.1×
P/S15.4×+8.7×

Profitability

See full
Operating margin10.2%+5.5pp
Net margin69.6%+64.0pp
FCF margin-320%-118pp

Returns & leverage

See full
Return on equity38.1%+35.2pp
Debt / equity1.3×0.0×
Current ratio3.6×-2.0×

Where this comes from

Reported directly by XOMA Corporation in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.

The official record: XOMA Corporation’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about XOMA Corporation's eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is XOMA Corporation's EPS (basic)?
XOMA Corporation (XOMA) reported EPS (basic) of $0.18 in Q1 2026.
How has XOMA Corporation's EPS (basic) changed year-over-year?
XOMA Corporation's EPS (basic) increased by 200.0% year-over-year, from $0.06 to $0.18.
What is the long-term trend for XOMA Corporation's EPS (basic)?
Over 4 years (2021 to 2025), XOMA Corporation's EPS (basic) has grown at a 21.6% compound annual growth rate (CAGR), from $0.70 to $1.53.
What does EPS (basic) mean?
Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.